Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer? Commentary Journal Article
| Author: | Seidman, A. D. |
| Article Title: | Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer? Commentary |
| Keywords: | cancer survival; treatment outcome; middle aged; cancer surgery; clinical trial; drug efficacy; antineoplastic agents; cancer adjuvant therapy; disease free survival; chemotherapy, adjuvant; cancer staging; recurrence risk; follow up; antineoplastic agent; metastasis; breast cancer; epidermal growth factor receptor 2; breast neoplasms; antibodies, monoclonal; heart failure; cardiotoxicity; short survey; receptor, erbb-2; symptomatology; trastuzumab; risk reduction; heart left ventricle ejection fraction; congestive heart failure; adjuvant; her2-positive; trastuzumab therapy |
| Journal Title: | Nature Clinical Practice Oncology |
| Volume: | 3 |
| Issue: | 4 |
| ISSN: | 1743-4254 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2006-04-01 |
| Start Page: | 178 |
| End Page: | 179 |
| Language: | English |
| DOI: | 10.1038/ncponc0460 |
| PUBMED: | 16596138 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 4 June 2012" - "Source: Scopus" |
